[{"address1": "11400 West Olympic Boulevard", "address2": "Suite 200", "city": "Los Angeles", "state": "CA", "zip": "90064", "country": "United States", "phone": "310 651 8041", "website": "https://www.immixbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.", "fullTimeEmployees": 18, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ilya  Rachman M.B.A., M.D., Ph.D.", "age": 53, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 712500, "exercisedValue": 0, "unexercisedValue": 120332}, {"maxAge": 1, "name": "Mr. Gabriel  Morris B.A.", "age": 39, "title": "CFO & Director", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 712500, "exercisedValue": 0, "unexercisedValue": 461582}, {"maxAge": 1, "name": "Dr. Graham  Ross FFPM, M.D.", "age": 65, "title": "Chief Medical Officer & Head of Clinical Development", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 88593, "exercisedValue": 0, "unexercisedValue": 5100}, {"maxAge": 1, "name": "Mr. Sean  Senn J.D., M.B.A., M.Sc.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.", "age": 78, "title": "Scientific Co-Founder", "yearBorn": 1947, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Marks MBBS, Ph.D.", "title": "Chief Medical Officer of Cell Therapy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mel  Davis-Pickett", "title": "Head of CMC Technical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael A. Grabow", "title": "Chief Commercial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.95, "open": 5.87, "dayLow": 5.75, "dayHigh": 6.2048, "regularMarketPreviousClose": 5.95, "regularMarketOpen": 5.87, "regularMarketDayLow": 5.75, "regularMarketDayHigh": 6.2048, "payoutRatio": 0.0, "beta": 0.311, "forwardPE": -12.404255, "volume": 864276, "regularMarketVolume": 864276, "averageVolume": 1036747, "averageVolume10days": 971730, "averageDailyVolume10Day": 971730, "bid": 4.44, "ask": 7.41, "bidSize": 2, "askSize": 2, "marketCap": 308728384, "fiftyTwoWeekLow": 1.34, "fiftyTwoWeekHigh": 7.73, "allTimeHigh": 8.68, "allTimeLow": 0.68, "fiftyDayAverage": 5.2337, "twoHundredDayAverage": 3.1477, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 180918032, "profitMargins": 0.0, "floatShares": 26750148, "sharesOutstanding": 52955130, "sharesShort": 2266456, "sharesShortPriorMonth": 1746822, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0428, "heldPercentInsiders": 0.22368, "heldPercentInstitutions": 0.062280003, "shortRatio": 2.23, "shortPercentOfFloat": 0.0545, "impliedSharesOutstanding": 52955130, "bookValue": 0.25, "priceToBook": 23.32, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -23562836, "trailingEps": -0.75, "forwardEps": -0.47, "enterpriseToEbitda": -7.59, "52WeekChange": 1.9897435, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 5.83, "targetHighPrice": 12.0, "targetLowPrice": 7.2, "targetMeanPrice": 9.6, "targetMedianPrice": 9.6, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 15947308, "totalCashPerShare": 0.475, "ebitda": -23836024, "totalDebt": 1106335, "quickRatio": 1.47, "currentRatio": 1.528, "debtToEquity": 13.386, "returnOnAssets": -0.66477996, "returnOnEquity": -1.82547, "freeCashflow": -6578808, "operatingCashflow": -14376895, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "IMMX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketChange": 0.010000229, "regularMarketChange": -0.119999886, "regularMarketDayRange": "5.75 - 6.2048", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1036747, "fiftyTwoWeekLowChange": 4.49, "fiftyTwoWeekLowChangePercent": 3.350746, "fiftyTwoWeekRange": "1.34 - 7.73", "fiftyTwoWeekHighChange": -1.9000001, "fiftyTwoWeekHighChangePercent": -0.24579561, "fiftyTwoWeekChangePercent": 198.97435, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755288000, "isEarningsDateEstimate": true, "corporateActions": [], "postMarketTime": 1769818508, "regularMarketTime": 1769806802, "exchange": "NCM", "messageBoardId": "finmb_417356223", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -2.016805, "shortName": "Immix Biopharma, Inc.", "longName": "Immix Biopharma, Inc.", "regularMarketPrice": 5.83, "marketState": "CLOSED", "epsTrailingTwelveMonths": -0.75, "epsForward": -0.47, "epsCurrentYear": -0.645, "priceEpsCurrentYear": -9.03876, "fiftyDayAverageChange": 0.5963001, "fiftyDayAverageChangePercent": 0.11393472, "twoHundredDayAverageChange": 2.6822999, "twoHundredDayAverageChangePercent": 0.85214597, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-12-16", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1639665000000, "postMarketChangePercent": 0.17153051, "postMarketPrice": 5.84, "displayName": "Immix Biopharma", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]